Company Reports

Recent Updates

All Reports

Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 95% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 90% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Stock Analyst Note

Vertex reported second-quarter revenue of $3.3 billion, a 12% increase year over year. Trikafta continued to anchor the cystic fibrosis franchise, comprising 75% of sales, while next-generation Alyftrek rose to 17% of sales. Vertex raised its 2026 revenue outlook by 96 basis points at the midpoint.
Stock Analyst Note

Vertex announced it will acquire Crinetics Pharmaceuticals for $85 per share (representing a 102% premium on its last closing price before the deal was announced), which marks Vertex's largest deal ever with a total equity value of $10 billion. Vertex's stock was down about 1.5% on July 7.
Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 90% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 90% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 90% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 90% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Stock Analyst Note

In the second quarter, Vertex reported a 12% revenue increase year over year and reiterated its 2025 financial guidance. Management announced its next-generation pain treatment, VX-993, would not advance after it failed to meet its primary endpoint, and shares declined 17% in early trading.
Company Report

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 90% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.
Stock Analyst Note

Narrow-moat Vertex Pharmaceuticals delivered softer-than-expected first-quarter results, as higher costs and weaker Trikafta revenue outside of the US weighed on the quarter's performance. While Trikafta sales in the US increased 9% to $1.66 billion thanks to strong patient demand and higher net realized pricing, Trikafta revenue outside of the US decreased 5% to $1.11 billion as strong international demand was offset by a revenue decline in Russia due to an unauthorized generic version on the market. Management believes this issue in Russia is a limited and isolated one, but it could potentially pose a risk to Trikafta sales. In addition, Vertex implemented a pause on its multiple ascending dose portion of the phase 1/2 study of VX-522, a nebulized CFTR mRNA therapy partnered with Moderna to assess a tolerability issue. We assign this pipeline candidate a 10% probability of approval due to its early stage of development. We think the decision to pause rather than an immediate discontinuation indicates that management is likely encouraged by the other data generated by the study.
Stock Analyst Note

Narrow-moat Vertex Pharmaceuticals reported solid year-end results, highlighted by revenue of $11 billion, representing a 12% increase over 2023. We forecast $12 billion in revenue in 2025, representing growth of about 9%. We maintain our fair value estimate of $356 per share, and continue to have a positive outlook for the firm as it diversifies its portfolio beyond cystic fibrosis, or CF.
Stock Analyst Note

Narrow-moat Vertex released results from its phase 2 trial of suzetrigine, for the treatment of painful lumbosacral radiculopathy, and it met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale. However, the placebo arm of the study also showed a similar within-group reduction in NPRS of 1.98. The comparison between the two cohorts spooked investors and shared tanked over 11%. We maintain our fair value estimate of $356 per share, and shares have moved into 3-star territory, trading about 11% above our fair value estimate.
Stock Analyst Note

Narrow-moat Vertex delivered solid third-quarter results, highlighted by a 12% increase in product revenue compared with the prior-year period. Strong demand for its triple-combination cystic fibrosis therapy, Trikafta/Kaftrio, delivered $2.58 billion in revenue, comprising 93% of the quarter’s product revenue. We appreciate that Vertex is progressing with its diverse pipeline of candidates. We forecast over $10.87 billion in total revenue in 2024, representing growth of about 10%. We maintain our fair value estimate of $356 per share, and we continue to have a positive outlook for the firm as it progresses in expanding its portfolio beyond cystic fibrosis.
Stock Analyst Note

Narrow-moat Vertex's second-quarter results were in line with our expectations. Product revenue of $2.65 billion represented a 6% increase compared with the prior-year period, and Vertex continues to make progress with its diverse pipeline candidates. Strong demand for its triple-combination cystic fibrosis therapy, Trikafta/Kaftrio, delivered $2.45 billion in revenue. Management slightly raised its 2024 revenue guidance by about 1% at the midpoint. We forecast over $10.83 billion in total revenue in 2024, representing growth of 9.8%. We maintain our fair value estimate of $356 per share, and we continue to have a positive outlook for the firm, as we forecast a five-year compound annual growth rate of 13%.

Sponsor Center